QTc shortening with a new investigational cancer drug: a brief case study (Q43008708)

12 November 2017

title

QTc shortening with a new investigational cancer drug: a brief case study (English)

1 reference

12 November 2017

Herbert M Himmel

1

1 reference

12 November 2017

Michael Hoffmann

series ordinal

2

1 reference

12 November 2017

publication date

4 June 2010

1 reference

Journal of Pharmacological and Toxicological Methods

12 November 2017

published in

1 reference

12 November 2017

volume

62

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

72-81

1 reference

Multiple downstream proarrhythmic targets for calmodulin kinase II: moving beyond an ion channel-centric focus

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Mutation in the KCNQ1 gene leading to the short QT-interval syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Short QT syndrome. Genotype-phenotype correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Regulation of an ERG K+ current by Src tyrosine kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Digitalis administration: an underappreciated but common cause of short QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

K+ channel structure-activity relationships and mechanisms of drug-induced QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Inhibition of IKs channels by HMR 1556.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Relative contributions of TRIaD and QT to proarrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Calmodulin kinase II inhibition shortens action potential duration by upregulation of K+ currents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Facts, fancies and follies of drug-induced QT/QTc interval shortening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Q-aTc interval as a clinical indicator of hypercalcemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Molecularly targeted oncology therapeutics and prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

An improved method to correct the QT interval of the electrocardiogram for changes in heart rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Modelling of short QT syndrome in a heterogeneous model of the human ventricular wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Clinical characteristics and treatment of short QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2010.05.012

10.1016/J.VASCN.2010.05.012

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference